基础胰岛素在2型糖尿病进阶治疗中的现代作用
本文综述了在胰高血糖素样肽1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂可用的背景下,基础胰岛素在2型糖尿病治疗中的现代定位。基础胰岛素已非生活方式加口服药控制不佳后的首选,但在代谢急症、新发糖尿病、隐匿性自身免疫糖尿病、妊娠及合并症限制其他药物时仍不可或缺,与新型药物联用可降低各自剂量、改善依从性与结局并减少副作用。
要点
- 基础胰岛素不再是生活方式加口服药不足后的首选,新型药物无需繁琐滴定且低血糖风险低。
- 基础胰岛素在代谢急症、新发糖尿病、隐匿性自身免疫糖尿病、妊娠等情形中仍不可或缺。
- 基础胰岛素与新型药物机制互补,联用可降低各自剂量、改善依从性与结局并减少副作用。
核心结论
- 基础胰岛素在控制高血糖及长期预防血管并发症中仍起关键作用,在多种临床情形中不可或缺。
- 基础胰岛素与新型药物联用可降低各自剂量、改善依从性与结局并减少副作用。
- 单用或联用的多种选择可依据精准医学原则更好匹配异质性2型糖尿病患者的临床表型。
主要发现
- 与基础胰岛素相比,新型药物仅需轻微滴定、以葡萄糖依赖方式降低高血糖并减轻体重。
- 新型药物可在短期内减少心肾事件。
- 基础胰岛素需用于其他疗法频繁无法使HbA1c达标和/或不能耐受时。
临床怎么用
- 基础胰岛素的使用在代谢急症、新发糖尿病、隐匿性自身免疫糖尿病、妊娠以及因合并症其他药物较不理想时至关重要。
- 基础胰岛素与其他疗法无法使HbA1c达标和/或不能耐受时需要使用。
- 基础胰岛素与新型药物机制不同但互补,联用可降低各自剂量、改善依从性与结局并减少副作用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Insulin deficiency, often aggravated by insulin resistance, results in type 2 diabetes mellitus (T2DM). With the availability of glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, basal insulin (BI) therapy is no longer the first-line option after lifestyle modification plus oral agents is insufficient. In contrast to BI, the newer medications require minor titration, lower hyperglycemia in a glucose-dependent manner, and reduce body weight. Importantly, the newer agents reduce cardiorenal events in the short term. Nonetheless, insulin therapy continues to play a key role in control of hyperglycemia and therefore long-term prevention of vascular complications. Its use is essential in many circumstances, including metabolic emergencies, new diabetes onset, latent autoimmune diabetes (LADA), pregnancy, and when other agents are less desirable due to comorbidities. BI is needed in the frequent condition of failure of other therapies to keep HbA1c to target and/or intolerance of them. There are several advantages to the combination of BI with the newer medications given their different but complementary mechanisms of action, primarily, the lower dose of each, improving adherence and outcomes while decreasing the side effects. Multiple choices for single or combination use can better meet the variety of clinical phenotypes in the heterogeneous T2DM population, using the tenets of precision medicine.
引用
- Bolli GB, Home PD, Porcellati F, et al. The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes. Diabetes Care. 2025. PMID: 40116796. doi:10.2337/dci24-0104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。